Values First Advisors Inc. Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Values First Advisors Inc. boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 32.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,511 shares of the medical equipment provider’s stock after buying an additional 371 shares during the period. Values First Advisors Inc.’s holdings in Intuitive Surgical were worth $510,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. Ausdal Financial Partners Inc. increased its holdings in shares of Intuitive Surgical by 1.5% in the 4th quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock valued at $739,000 after acquiring an additional 33 shares during the last quarter. Modera Wealth Management LLC lifted its position in Intuitive Surgical by 2.0% during the 3rd quarter. Modera Wealth Management LLC now owns 1,715 shares of the medical equipment provider’s stock worth $501,000 after acquiring an additional 34 shares during the period. Pure Financial Advisors LLC lifted its position in Intuitive Surgical by 2.4% during the 4th quarter. Pure Financial Advisors LLC now owns 1,432 shares of the medical equipment provider’s stock worth $483,000 after acquiring an additional 34 shares during the period. Arthur M. Cohen & Associates LLC lifted its position in Intuitive Surgical by 0.4% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 8,850 shares of the medical equipment provider’s stock worth $2,986,000 after acquiring an additional 34 shares during the period. Finally, Prime Capital Investment Advisors LLC lifted its position in Intuitive Surgical by 2.2% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 1,702 shares of the medical equipment provider’s stock worth $497,000 after acquiring an additional 37 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling

In related news, VP Fredrik Widman sold 5,041 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares of the company’s stock, valued at $43,677.70. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Myriam Curet sold 4,318 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the completion of the sale, the executive vice president now directly owns 189 shares in the company, valued at $69,958.35. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the transaction, the vice president now owns 110 shares in the company, valued at $43,677.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,418 shares of company stock worth $95,927,097. 0.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ISRG has been the subject of several recent analyst reports. Morgan Stanley raised their price target on Intuitive Surgical from $300.00 to $330.00 and gave the company an “equal weight” rating in a report on Monday, December 4th. Barclays raised their price target on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Mizuho lifted their price objective on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Wells Fargo & Company lifted their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Finally, Piper Sandler lifted their price objective on Intuitive Surgical from $325.00 to $425.00 and gave the stock an “overweight” rating in a report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $371.60.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded down $1.01 during midday trading on Thursday, reaching $399.09. The stock had a trading volume of 1,124,747 shares, compared to its average volume of 1,673,996. Intuitive Surgical, Inc. has a twelve month low of $246.63 and a twelve month high of $403.76. The stock has a market capitalization of $141.46 billion, a PE ratio of 79.30, a price-to-earnings-growth ratio of 6.17 and a beta of 1.36. The stock’s 50-day simple moving average is $385.19 and its 200 day simple moving average is $332.83.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The company had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter in the previous year, the firm posted $0.91 earnings per share. The firm’s quarterly revenue was up 16.6% on a year-over-year basis. Equities analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.